New Tuberculosis Management

Disclaimer: This document provides comprehensive medical information for educational and clinical reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment in the context of individual patient circumstances, local epidemiology, and current national/international guidelines. Drug dosages, laboratory values, and treatment protocols are subject to change and should be verified with official prescribing information and the latest guidelines.

Overview

• Definition: Tuberculosis (TB) is a chronic infectious disease caused by bacteria of the Mycobacterium tuberculosis complex, primarily Mycobacterium tuberculosis. "New Tuberculosis Management" typically refers to the diagnosis and treatment of individuals with active, drug-susceptible TB disease who have never been treated for TB or have been treated for less than one month.
• Epidemiology:
  • TB remains one of the world's deadliest infectious diseases. Globally, an estimated 10.6 million people fell ill with TB in 2022, and 1.3 million died from it (WHO Global TB Report 2023).
  • Geographical Burden: Most cases occur in the WHO South-East Asia and African Regions, with India, Indonesia, China, the Philippines, Pakistan, and Nigeria accounting for the largest share.
  • Demographics: All age groups are at risk, but TB disproportionately affects adults in their most productive years. Men account for a higher proportion of cases (55%), while women account for 33% and children 12%.
  • Key Co-morbidities: HIV co-infection significantly increases the risk of active TB, as does diabetes, malnutrition, and other immunosuppressive conditions.
• Classification:
  • Latent TB Infection (LTBI): Individuals infected with M. tuberculosis but who do not have active TB disease, are asymptomatic, and are not infectious. Approximately one-quarter of the world's population has LTBI.
  • Active TB Disease:
    • Pulmonary TB: Affects the lungs, representing the most common form (approximately 85% of cases) and the primary driver of transmission.
    • Extrapulmonary TB (EPTB): Affects organs other than the lungs, such as lymph nodes, pleura, bones and joints, meninges, abdomen, genitourinary tract, or disseminated (miliary TB). EPTB is more common in immunocompromised individuals (e.g., HIV-positive).
    • Drug-Susceptible TB: The bacteria are susceptible to first-line anti-TB drugs. This is the focus of "New TB Management."
    • Drug-Resistant TB (DR-TB): TB caused by bacteria resistant to at least one first-line anti-TB drug. Multidrug-resistant TB (MDR-TB) is resistant to at least isoniazid and rifampicin. Extensively drug-resistant TB (XDR-TB) is resistant to isoniazid, rifampicin, any fluoroquinolone, and at least one of the Group A second-line injectables (or newer agents like bedaquiline or linezolid). Management of DR-TB differs significantly and is beyond the scope of this "New TB Management" document.

Pathophysiology

• Mechanism:
  1. Transmission: M. tuberculosis is primarily transmitted person-to-person via airborne droplet nuclei (aerosols) generated by individuals with active pulmonary or laryngeal TB disease when they cough, sneeze, speak, or sing.
  2. Inhalation and Primary Infection: Inhaled bacilli are deposited in the alveolar spaces. Alveolar macrophages phagocytose the bacilli. In most cases, the macrophages kill the bacilli or wall them off, leading to containment and LTBI.
  3. Immune Response: The host's cellular immune response (primarily T-lymphocytes) forms granulomas (Ghon focus/complex) to contain the infection, often calcifying. This typically occurs 2-10 weeks post-exposure.
  4. Latent Infection: Bacilli remain viable but dormant within the granulomas. Individuals are asymptomatic and not infectious. Approximately 5-10% of individuals with LTBI will develop active TB disease during their lifetime, with half of these developing it within the first two years of infection.
  5. Reactivation (Active Disease): When host immunity wanes (e.g., due to HIV, immunosuppressive therapy, malnutrition, aging), dormant bacilli can reactivate, multiply, and cause active disease. The disease can spread locally within the lungs or hematogenously/lymphatically to other sites, causing extrapulmonary TB. Caseating necrosis and cavitation (in the lungs) are hallmarks of active disease, leading to high bacterial loads and infectivity.
• Risk Factors:
  • Immunosuppression:
    • HIV infection (most significant risk factor, 20-fold increased risk of active TB).
    • Immunosuppressive medications (e.g., TNF-α inhibitors, systemic corticosteroids >15 mg prednisone equivalent/day for >1 month).
    • Solid organ or hematopoietic stem cell transplant recipients.
    • Malignancy (especially leukemia, lymphoma, head and neck cancer).
    • End-stage renal disease (ESRD) requiring dialysis.
    • Diabetes mellitus (3-fold increased risk).
    • Silicosis (30-fold increased risk).
    • Malnutrition/underweight (BMI <18.5 kg/m²).
  • Exposure-Related:
    • Close contact with an individual with active, infectious TB (especially pulmonary).
    • Residence in or travel to high-TB prevalence areas.
    • Congregate settings (e.g., correctional facilities, homeless shelters, long-term care facilities).
    • Healthcare workers with occupational exposure.
  • Social/Environmental:
    • Poverty, homelessness, substance abuse (alcoholism, intravenous drug use).
    • Tobacco smoking (nearly doubles the risk of TB and death).
• Protective Factors:
  • BCG Vaccination: Provides variable protection against pulmonary TB in adults, but offers significant protection against severe forms of TB in children (e.g., TB meningitis, disseminated TB). Not routinely recommended in countries with low TB incidence.
  • Good Nutrition and Health Status: A strong immune system is crucial for containing primary infection and preventing reactivation.
  • Early Diagnosis and Treatment of LTBI: Identifying and treating individuals with LTBI prevents progression to active disease.
  • Infection Control Measures: Prompt diagnosis and treatment of active cases, respiratory hygiene, adequate ventilation in healthcare settings, and use of personal protective equipment (e.g., N95 respirators) prevent transmission.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Chronic cough: Often productive, lasting ≥2-3 weeks (most common symptom of pulmonary TB).
  • Fever: Low-grade, often persistent.
  • Night sweats: Drenching sweats, especially during sleep.
  • Weight loss: Unexplained, progressive.
  • Fatigue/Malaise: General feeling of being unwell, lethargy.
• Early Signs: May be subtle and non-specific, leading to delayed diagnosis.
  • Mild, persistent cough.
  • Low-grade fever.
  • Fatigue.
  • Anorexia.
• Advanced Signs: Reflect more severe or widespread disease.
  • Hemoptysis: Coughing up blood, indicative of lung damage (e.g., cavitation).
  • Dyspnea: Shortness of breath, especially with exertion, indicating significant lung involvement or pleural effusion.
  • Chest pain: Pleuritic chest pain (sharp, worsens with breathing) if pleura involved.
  • Cachexia: Severe wasting and malnutrition.
  • Extrapulmonary Symptoms: Swollen, painful lymph nodes (lymphadenitis); back pain/stiffness, neurological deficits (Pott's disease); headache, stiff neck, altered mental status (TB meningitis); abdominal pain, ascites (abdominal TB); painful joints (bone/joint TB).
• Atypical Presentations: More common in immunocompromised individuals (e.g., HIV, elderly, very young).
  • Minimal or absent cough in pulmonary TB.
  • Absence of classic granulomas on biopsy.
  • Diffuse or miliary infiltrates on chest X-ray without clear cavitary lesions.
  • Predominant extrapulmonary disease without obvious pulmonary involvement.
  • Lack of constitutional symptoms.

Physical Examination

Physical findings are often non-specific and may be normal, especially in early or mild disease.

• Inspection:
  • General: Cachexia, pallor, signs of chronic illness.
  • Respiratory: Tachypnea, use of accessory muscles (in severe disease), reduced chest wall expansion on the affected side.
  • Extrapulmonary: Lymphadenopathy (cervical, supraclavicular, axillary most common), joint swelling, skin lesions (lupus vulgaris, scrofuloderma).
• Palpation:
  • Lymphadenopathy: Palpable, often firm, non-tender, matted lymph nodes (e.g., in TB lymphadenitis).
  • Respiratory: Decreased tactile fremitus over areas of pleural effusion or consolidation.
  • Abdomen: Tenderness, hepatosplenomegaly, palpable masses (abdominal TB).
• Percussion:
  • Dullness over areas of consolidation (lobar pneumonia-like) or pleural effusion.
  • Hyper-resonance (rare) over compensatory emphysema.
• Auscultation:
  • Pulmonary TB:
    • Crackles (rales): Commonly heard over affected areas, especially upper lobes.
    • Bronchial breath sounds: Over areas of consolidation.
    • Diminished breath sounds: Over pleural effusions or destroyed lung parenchyma.
    • Amphoric breath sounds: Over large cavities.
  • Pleural Effusion: Decreased or absent breath sounds, egophony, pleural friction rub (rare).
  • Cardiac: Pericardial friction rub (TB pericarditis), distant heart sounds.

Diagnostic Approach

Timely and accurate diagnosis is critical for effective treatment and preventing transmission.

History Taking

• Key Questions:
  • Symptoms: Onset, duration, character of cough (productive? hemoptysis?), fever (timing, severity), night sweats, weight loss (amount, timeframe), fatigue, chest pain, dyspnea.
  • Exposure History: Contact with known TB cases (household, workplace, social), duration and intensity of exposure.
  • Travel/Residence History: Previous or current residence in, or travel to, high TB prevalence areas.
  • Past Medical History: Previous TB diagnosis or treatment (date, drugs, duration, outcome), HIV status, diabetes, renal disease, malignancy, organ transplant, silicosis, history of immunosuppressive medication use (e.g., biologics, corticosteroids).
  • Social History: Housing status, homelessness, substance use (alcohol, illicit drugs), incarceration, occupational risk (healthcare worker).
  • Vaccination Status: BCG history.
• Red Flags:
  • Hemoptysis (requires urgent evaluation).
  • Respiratory distress or signs of respiratory failure.
  • Neurological symptoms (headache, stiff neck, altered mental status, focal neurological deficits) suggesting TB meningitis.
  • Unexplained significant weight loss and wasting.
  • Clinical suspicion of miliary TB (diffuse constitutional symptoms, hepatosplenomegaly, pancytopenia).

Laboratory Tests

• First-Line:
  • Sputum Acid-Fast Bacilli (AFB) Smear Microscopy:
    • Rationale: Rapid, inexpensive, identifies highly infectious cases. Visualizes mycobacteria.
    • Procedure: Collect at least three sputum samples (preferably morning specimens) over 1-3 days.
    • Interpretation: Positive smear suggests active mycobacterial disease but does not differentiate M. tuberculosis from non-tuberculous mycobacteria (NTM). Sensitivity is ~50-70% in culture-confirmed cases.
  • Nucleic Acid Amplification Tests (NAATs):
    • Rationale: Rapid (results within hours), highly sensitive and specific for M. tuberculosis complex, and can simultaneously detect rifampicin resistance. Recommended by WHO as the initial diagnostic test in individuals with signs and symptoms of TB.
    • Examples: Xpert MTB/RIF (and Xpert MTB/RIF Ultra), Truenat MTB.
    • Specimens: Sputum (including induced sputum), bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), lymph node aspirates, tissue biopsies.
    • Interpretation: Positive indicates presence of M. tuberculosis DNA. Detection of rifampicin resistance mutation indicates high likelihood of MDR-TB, requiring urgent confirmatory DST.
• Confirmatory:
  • Mycobacterial Culture:
    • Rationale: Gold standard for TB diagnosis. Allows for definitive identification of M. tuberculosis complex and comprehensive drug susceptibility testing (DST).
    • Procedure: All suspected TB specimens (sputum, tissue, fluids) should be cultured.
    • Methods: Solid media (e.g., Löwenstein-Jensen) or liquid media (e.g., BACTEC MGIT 960). Liquid cultures yield faster results (1-3 weeks vs. 3-8 weeks for solid).
    • Interpretation: Positive culture confirms active TB.
  • Drug Susceptibility Testing (DST):
    • Rationale: Essential for all new TB cases to detect primary drug resistance and guide treatment.
    • Methods: Phenotypic (culture-based) and genotypic (molecular). Molecular DST (e.g., Line Probe Assay, next-generation sequencing) can rapidly detect resistance to first-line drugs.
• Monitoring:
  • Sputum Smear and Culture:
    • Frequency: Monthly until conversion to negative (typically 2 consecutive negative cultures, 1 week apart).
    • Rationale: To assess treatment response and confirm bacterial clearance.
  • Liver Function Tests (LFTs): ALT, AST, bilirubin, alkaline phosphatase.
    • Frequency: Baseline, then typically monthly, or more frequently if signs of hepatotoxicity appear.
    • Rationale: To monitor for drug-induced liver injury (isoniazid, rifampicin, pyrazinamide are hepatotoxic).
  • Renal Function (Creatinine, BUN): Baseline and as clinically indicated, especially with ethambutol or pyrazinamide in patients with renal impairment.
  • Complete Blood Count (CBC): Baseline and as clinically indicated, to monitor for hematologic toxicities (rarely from rifampicin, pyrazinamide).
  • Uric Acid: Baseline and as clinically indicated, especially if symptoms of gout develop (pyrazinamide can cause hyperuricemia).
  • HIV Testing: All TB patients should be offered HIV testing (WHO recommendation).
  • Hepatitis B/C Screening: Recommended due to shared risk factors and potential for co-hepatotoxicity with TB drugs.

Imaging

• Recommended:
  • Chest X-ray (CXR):
    • Rationale: Standard initial imaging for suspected pulmonary TB. Helps to localize disease, assess extent, and identify characteristic patterns.
    • Typical Findings (Pulmonary TB):
      • Post-primary (reactivation) TB: Infiltrates (often cavitary) predominantly in the upper lobes (apical and posterior segments) or superior segments of lower lobes.
      • Primary TB (often in children/immunocompromised): Hilar or mediastinal lymphadenopathy, pleural effusion, lower/middle lobe infiltrates.
      • Miliary TB: Diffuse, fine, granular (millet seed-like) infiltrates throughout both lung fields.
      • Other: Pleural effusion, bronchiectasis, fibrosis, calcified granulomas (healed lesions).
• Advanced:
  • Computed Tomography (CT) Scan of the Chest:
    • Rationale: Offers higher resolution than CXR, better for visualizing subtle parenchymal lesions, extent of cavitation, lymphadenopathy, pleural disease, and differentiating TB from other lung diseases. Essential for complex cases or when CXR is ambiguous.
  • CT/MRI for Extrapulmonary TB:
    • Rationale: Used to localize and characterize EPTB lesions.
    • Examples:
      • Brain CT/MRI: For suspected TB meningitis or tuberculomas.
      • Spinal MRI: For suspected Pott's disease (vertebral TB).
      • Abdominal CT: For suspected abdominal TB (lymphadenopathy, ascites, organ involvement).
      • Ultrasound: Can be useful for lymphadenopathy, ascites, or genitourinary TB.

Management

Acute Management

• Immediate:
  • Infection Control: Place patients with suspected or confirmed pulmonary TB on airborne precautions in a negative-pressure room (if available) or well-ventilated area. Instruct patients on respiratory hygiene (cough etiquette, mask use).
  • Empiric Therapy: Initiate anti-TB treatment immediately if there is a strong clinical suspicion of active TB (based on symptoms, risk factors, CXR findings), especially in high-prevalence settings or in severe/disseminated disease (e.g., TB meningitis, miliary TB), even before culture confirmation. Delay in treatment can worsen prognosis and increase transmission.
  • Contact Investigation: Initiate identification and screening of close contacts.
• Stabilization:
  • Address acute respiratory distress (oxygen therapy, bronchodilators if indicated).
  • Manage fluid and electrolyte imbalances.
  • Ensure adequate nutrition.
• Emergency:
  • Massive Hemoptysis: Secure airway, position patient with bleeding lung down, consider bronchoscopy for localization, interventional radiology for embolization, or surgical resection in refractory cases.
  • Respiratory Failure: Mechanical ventilation may be required.
  • TB Meningitis: Prompt initiation of anti-TB drugs with good CNS penetration, often combined with corticosteroids (dexamethasone) to reduce inflammation and neurological sequelae.
  • Spinal TB with Neurological Compromise: Urgent orthopedic or neurosurgical consultation to prevent irreversible damage.

Chronic Management

• Pharmacological:
  • Standard Short-Course Chemotherapy (SSCC) for Drug-Susceptible TB:
    • The cornerstone of drug-susceptible TB treatment is a multi-drug regimen delivered over 6 months, using Directly Observed Therapy (DOT).
    • Rationale for Multi-drug Regimen: Prevents the emergence of drug resistance by targeting different bacterial mechanisms and ensures eradication of diverse bacterial populations (rapidly multiplying, slowly multiplying, persistent).
    • Rationale for DOT: Ensures adherence, reduces drug resistance, and improves treatment outcomes.
    • Regimen: Two phases:
      1. Intensive Phase (Initial Phase): 2 months of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) (2HRZE daily).
         • Purpose: Rapidly kill highly multiplying bacilli, prevent resistance, and render the patient non-infectious quickly.
      2. Continuation Phase: 4 months of Isoniazid (H) and Rifampicin (R) (4HR daily).
         • Purpose: Eradicate persistent bacilli to prevent relapse.
    • Drug Dosages (Adults, daily dosing):
      • Isoniazid (H): 5 mg/kg (range 4-6 mg/kg) orally once daily; maximum 300 mg/day. (Often given with pyridoxine 25-50 mg daily to prevent peripheral neuropathy, especially in those with risk factors like diabetes, HIV, malnutrition, pregnancy, alcoholism, ESRD).
      • Rifampicin (R): 10 mg/kg (range 8-12 mg/kg) orally once daily; maximum 600 mg/day.
      • Pyrazinamide (Z): 20-25 mg/kg (range 15-30 mg/kg) orally once daily; maximum 2000 mg/day.
      • Ethambutol (E): 15-20 mg/kg (range 15-25 mg/kg) orally once daily; maximum 1600 mg/day.
    • Frequency: Daily dosing is preferred. Intermittent dosing (e.g., three times weekly) is an option for the continuation phase in some settings, but daily dosing is generally more effective and less likely to lead to resistance if adherence is suboptimal.
    • Important Considerations:
      • Drug-drug interactions: Rifampicin is a potent inducer of CYP450 enzymes, leading to significant interactions with many drugs (e.g., antiretrovirals, oral contraceptives, warfarin, corticosteroids, antidiabetic drugs). Careful review of all medications is essential.
      • Adverse Drug Reactions: Monitor closely (see Complications section).
      • Extrapulmonary TB: For most forms of EPTB (e.g., lymph node, pleural, bone/joint), the standard 6-month HRZE/HR regimen is effective. However, TB meningitis and some severe forms of osteoarticular TB may require longer durations (9-12 months) and/or adjunctive corticosteroids.
• Non-pharmacological:
  • Nutritional Support: Address malnutrition, provide dietary counseling.
  • Patient Education: Explain the disease, treatment regimen, importance of adherence, potential side effects, and infection control measures.
  • Psychosocial Support: Address mental health issues, stigma, and provide support services (housing, financial).
  • Infection Control: Educate patients on cough etiquette and ensure continued airborne precautions until smear conversion (typically after 2-3 weeks of effective treatment and clinical improvement).
• Monitoring:
  • Clinical Monitoring: Monthly assessment of symptoms (cough, fever, weight, general well-being) and adherence.
  • Bacteriological Monitoring:
    • Pulmonary TB: Sputum AFB smear and culture at months 2, 5, and 6 (or until two consecutive negative cultures). Culture conversion (usually by month 2) is a critical indicator of treatment success. If cultures remain positive at month 2, assess adherence and consider drug resistance.
    • Extrapulmonary TB: Monitoring is primarily clinical.
  • Adverse Drug Reactions: Regular assessment for side effects (e.g., hepatotoxicity, neuropathy, visual changes).
  • Weight Monitoring: Monthly to assess nutritional status and response to treatment.

Treatment Algorithms

• First-Line (New, Drug-Susceptible TB):
  • Pulmonary TB:
    • Intensive Phase: HRZE daily for 2 months.
    • Continuation Phase: HR daily for 4 months.
    • Total Duration: 6 months.
  • Extrapulmonary TB (most forms, e.g., pleural, lymph node, peripheral joint, genitourinary):
    • Same 6-month HRZE/HR regimen.
  • TB Meningitis, Osteoarticular TB (spine, weight-bearing joints):
    • Intensive Phase: HRZE daily for 2 months.
    • Continuation Phase: HR daily for 7-10 months.
    • Total Duration: 9-12 months.
    • Adjunctive Corticosteroids: Dexamethasone is recommended for TB meningitis (e.g., 0.4 mg/kg/day for 4 weeks, then tapered over 4 weeks) and possibly for TB pericarditis (e.g., 60 mg prednisone daily, tapered over 6-8 weeks) to reduce inflammation and complications.
• Second-Line (for cases of confirmed drug resistance):
  • Beyond the scope of "New TB Management." Involves regimens with fluoroquinolones, injectable agents (e.g., amikacin, capreomycin, streptomycin - though injectables are increasingly being replaced by all-oral regimens), and newer drugs (e.g., bedaquiline, delamanid, linezolid). Regimens are longer (e.g., 9-18 months) and have more side effects. Always guided by full DST.
• Refractory Cases:
  • Definition: Failure of treatment, relapse, or persistent positive cultures despite adequate adherence to a first-line regimen.
  • Management:
    1. Re-evaluate Adherence: Reinforce DOT.
    2. Confirm Drug Susceptibility: Repeat sputum culture and DST (phenotypic and molecular) to detect acquired drug resistance.
    3. Rule out Malabsorption: Consider drug malabsorption in patients with underlying gastrointestinal conditions (e.g., HIV enteropathy, bariatric surgery).
    4. Review Diagnosis: Reconsider alternative diagnoses (e.g., NTM, malignancy) if initial diagnosis was not definitive.
    5. Consult Experts: Refer to a TB specialist or expert committee for management of complex or drug-resistant cases.

Complications

Common (related to drugs or disease)

• Drug-Induced Liver Injury (DILI): Elevated LFTs, nausea, vomiting, abdominal pain, jaundice. Most common with isoniazid, rifampicin, and pyrazinamide. Monitor LFTs monthly.
  • Management: Discontinue hepatotoxic drugs if AST/ALT >5x upper limit of normal (ULN) without symptoms, or >3x ULN with symptoms. Re-introduce drugs sequentially after LFTs normalize.
• Gastrointestinal Distress: Nausea, vomiting, abdominal pain, anorexia (common with all first-line drugs).
• Peripheral Neuropathy: Numbness, tingling, pain in extremities (isoniazid, especially in malnourished, diabetic, HIV-positive, alcoholic patients). Prevented/treated with pyridoxine (vitamin B6).
• Optic Neuritis: Blurred vision, red-green color blindness (ethambutol). Requires baseline and monthly vision checks.
• Hyperuricemia/Arthralgia: Joint pain, gout flares (pyrazinamide).
• Orange/Red Secretions: Urine, tears, sweat, contact lenses (rifampicin). Benign but patients need to be warned.
• Skin Rash: Various forms, sometimes severe.
• Flu-like Syndrome: Fever, chills, muscle aches (rifampicin, often with intermittent dosing).
• Thrombocytopenia, Hemolytic Anemia: Rare, usually rifampicin-induced.

Serious (life-threatening or severe disability)

• Respiratory Failure: Due to extensive lung destruction, massive hemoptysis, or severe pleural effusion.
• Massive Hemoptysis: Bleeding >200-600 mL in 24 hours, can be fatal.
• Cor Pulmonale: Right-sided heart failure due to chronic pulmonary hypertension from extensive lung damage.
• Permanent Lung Damage: Bronchiectasis, extensive fibrosis, loss of lung volume, leading to chronic respiratory insufficiency.
• Spinal Deformity (Pott's Disease): Vertebral collapse, kyphosis (humpback), paravertebral abscesses, leading to pain and neurological deficits (paraplegia/paresis).
• TB Meningitis: Hydrocephalus, stroke, cranial nerve palsies, permanent neurological deficits, cognitive impairment, death.
• Adrenal Insufficiency (Addison's Disease): If adrenal glands are destroyed by TB.
• Disseminated TB (Miliary TB): Multi-organ failure, shock, death.
• Immune Reconstitution Inflammatory Syndrome (IRIS): In HIV-TB co-infected patients starting antiretroviral therapy (ART), paradoxical worsening of TB symptoms or appearance of new lesions due to immune recovery.

Long-term

• Post-TB Lung Disease: Chronic cough, dyspnea, recurrent infections, bronchiectasis, aspergilloma formation in cavities.
• Neurological Deficits: From TB meningitis (e.g., epilepsy, cognitive impairment, visual/auditory impairment).
• Chronic Pain: From musculoskeletal involvement (e.g., spinal TB, joint destruction).
• Infertility: If genitourinary TB is severe.
• Psychosocial Sequelae: Stigma, depression, anxiety, social isolation.

Prognosis

• Factors Affecting Outcome:
  • Early Diagnosis and Treatment: Crucial for good prognosis and preventing severe complications.
  • Adherence to Treatment: Complete and uninterrupted treatment is the single most important factor for cure and preventing relapse and drug resistance.
  • Drug Susceptibility: Drug-susceptible TB has an excellent prognosis.
  • Host Immunity: Immunocompromised individuals (e.g., HIV-positive, diabetic, malnourished) have a higher risk of treatment failure, relapse, and mortality.
  • Extent and Form of Disease: Extensive cavitary pulmonary TB or severe extrapulmonary forms (meningitis, disseminated) have a worse prognosis.
  • Co-morbidities: Diabetes, chronic kidney disease, liver disease worsen outcomes.
• Survival: With appropriate and adherent treatment for drug-susceptible TB, cure rates exceed 95%. Mortality is low, usually associated with severe disease at presentation or significant co-morbidities.
• Quality of Life: Can be excellent after successful treatment, but may be significantly impacted by long-term complications (e.g., chronic lung disease, neurological deficits), especially if diagnosis or treatment was delayed. Stigma and psychosocial factors can also affect quality of life.

Prevention

Primary (Preventing initial infection or progression to active disease)

• Infection Control:
  • Early diagnosis and prompt, effective treatment of active TB cases to interrupt transmission.
  • Isolation of infectious patients in healthcare settings (negative-pressure rooms, N95 respirators for healthcare workers).
  • Administrative controls (e.g., cough etiquette, patient education).
  • Environmental controls (e.g., adequate ventilation, UV germicidal irradiation).
• BCG Vaccination:
  • Rationale: Protects against severe forms of TB (meningitis, miliary TB) in infants and young children. Efficacy against adult pulmonary TB is variable.
  • Recommendation: Recommended in countries with high TB burden. Not routinely recommended in low-incidence countries due to limited efficacy against adult pulmonary TB and interference with TST interpretation.
• Treatment of Latent TB Infection (LTBI):
  • Rationale: Prevents progression from LTBI to active TB disease.
  • Target Populations: Close contacts of active TB cases, HIV-positive individuals, immunocompromised patients, recent immigrants from high-prevalence areas, individuals with fibrotic lesions on CXR suggestive of prior TB.
  • Regimens:
    • Isoniazid (H): Daily for 6 or 9 months (6H or 9H). 9 months is preferred for HIV-positive individuals.
    • Rifampicin (R): Daily for 4 months (4R).
    • Isoniazid and Rifapentine (HP): Weekly for 3 months (3HP), via DOT.
    • Choice depends on local guidelines, drug-drug interactions, and patient factors.

Secondary (Early detection and intervention)

• Contact Investigation: Systematic identification, screening (TST or IGRA), and evaluation of individuals exposed to an infectious TB case.
• Targeted Screening: Screening of high-risk populations (e.g., incarcerated persons, homeless, people with HIV, healthcare workers) for LTBI or active disease.
• Pre-transplant Screening: All solid organ transplant candidates and recipients, as well as those on immunosuppressive therapy (e.g., TNF-α inhibitors), should be screened for LTBI and treated if positive.

Tertiary (Preventing complications and sequelae)

• Complete Treatment of Active TB: Ensures cure, prevents relapse, development of drug resistance, and long-term complications.
• Management of Complications: Timely and appropriate management of acute complications (e.g., hemoptysis, meningitis) and long-term sequelae (e.g., post-TB lung disease, neurological deficits).
• Rehabilitation: Physical, occupational, and psychological rehabilitation for patients with significant sequelae.

Special Populations

• Pediatric:
  • Diagnosis: More challenging due to non-specific symptoms, difficulty obtaining sputum, and lower bacillary load. Gastric aspirates, induced sputum, and extrapulmonary samples are often used. CXR findings can be atypical (e.g., primary complex, hilar adenopathy).
  • Treatment: Standard 6-month HRZE/HR regimen is generally used, but dosages are weight-based. Ethambutol may be used in young children if severe disease or high risk of resistance, but typically avoided in those too young to report visual symptoms. Close monitoring for drug toxicity.
  • BCG: Recommended at birth in high-burden countries.
  • Corticosteroids: Often used in TB meningitis and severe lymphadenitis/pericarditis.
• Geriatric:
  • Presentation: Often atypical (e.g., less cough, more constitutional symptoms like fatigue and weight loss, or predominant extrapulmonary disease). May mimic malignancy or other chronic diseases.
  • Diagnosis: Higher threshold for suspicion. Immunological tests for LTBI (TST/IGRA) may be less reliable due to immunosenescence.
  • Treatment: Increased risk of adverse drug reactions (hepatotoxicity, peripheral neuropathy, optic neuritis) due to age-related physiological changes, polypharmacy, and co-morbidities. Careful dose adjustments for renal/hepatic impairment. Drug-drug interactions with rifampicin are common.
• Pregnancy:
  • Diagnosis: Standard diagnostic methods are safe. CXR with abdominal shielding is considered safe.
  • Treatment: First-line drugs (isoniazid, rifampicin, ethambutol) are generally considered safe throughout pregnancy. Pyrazinamide is generally included in the regimen by WHO and CDC, as the benefit outweighs potential risk. Streptomycin is contraindicated due to ototoxicity in the fetus.
  • Pyridoxine: Essential with isoniazid to prevent peripheral neuropathy in the mother and potentially in the fetus.
  • Monitoring: Close monitoring for drug toxicity and adherence. Breastfeeding is generally safe while on first-line TB drugs.
• Comorbidities:
  • HIV Co-infection:
    • Increased Risk: HIV-positive individuals have a significantly higher risk of developing active TB and extrapulmonary forms.
    • Presentation: Often atypical, less cavitation, more diffuse infiltrates, higher rates of smear-negative TB.
    • Treatment: Standard 6-month HRZE/HR regimen for drug-susceptible TB. Longer regimens (e.g., 9 months for some forms) may be considered for severe immune suppression.
    • Drug-drug Interactions: Rifampicin interacts significantly with many antiretroviral drugs (especially protease inhibitors and non-nucleoside reverse transcriptase inhibitors). Consultation with HIV/TB co-management specialists is essential. Rifabutin may be used as an alternative to rifampicin to reduce interactions with certain ARTs, or specific ART regimens compatible with rifampicin (e.g., dolutegravir-based) should be chosen.
    • IRIS: Immune Reconstitution Inflammatory Syndrome can occur when ART is started during TB treatment. Timing of ART initiation is crucial (usually 2-8 weeks after starting TB treatment, earlier for TB meningitis).
  • Diabetes Mellitus:
    • Increased Risk: Diabetes increases the risk of active TB, treatment failure, and relapse.
    • Management: Meticulous glycemic control is important for improving TB outcomes. Monitor for drug interactions with oral hypoglycemics.
  • Renal Impairment:
    • Dose Adjustment: Ethambutol and pyrazinamide dosages must be adjusted according to creatinine clearance (e.g., 2-3 times/week for severe impairment or dialysis). Isoniazid and rifampicin generally do not require dose adjustment for renal impairment.
    • Monitoring: Increased risk of drug toxicity.
  • Hepatic Impairment:
    • Risk: Increased risk of hepatotoxicity with first-line drugs.
    • Management: May require modification of the regimen (e.g., avoiding pyrazinamide, using regimens like RH-E or RH-Lfx for 9-12 months) and very close monitoring of LFTs.

Clinical Pearls

• Diagnostic:
  • "Think TB": Maintain a high index of suspicion for TB in patients with persistent cough (>2-3 weeks), unexplained fever, night sweats, or weight loss, especially in high-risk populations or those with a history of exposure.
  • NAATs are Game Changers: Utilize Nucleic Acid Amplification Tests (e.g., Xpert MTB/RIF) as the initial diagnostic test for active TB. They offer rapid diagnosis and simultaneous detection of rifampicin resistance, guiding early management decisions.
  • Always Get DST: Every patient with confirmed M. tuberculosis should have drug susceptibility testing performed (ideally for all first-line drugs) to rule out primary drug resistance.
  • Extrapulmonary TB: Can be challenging to diagnose; require high suspicion and appropriate specimen collection (biopsy, aspirate) for microscopy, NAAT, and culture.
• Treatment:
  • DOT is Standard: Directly Observed Therapy (DOT) is the standard of care for all TB patients to ensure adherence and prevent the development of drug resistance.
  • Monitor for Adverse Effects: Actively inquire about and monitor for drug side effects. Educate patients on symptoms of hepatotoxicity, neuropathy, and visual changes. Promptly address side effects to maintain adherence.
  • Manage Drug Interactions: Rifampicin has numerous significant drug interactions. Thoroughly review all patient medications and consult specialists (e.g., HIV specialists, pharmacists) as needed.
  • Culture Conversion is Key: Monitor sputum cultures regularly to confirm bacterial clearance. Persistent positive cultures at month 2-3 indicate treatment failure, non-adherence, or drug resistance.
  • Treat LTBI: Proactive identification and treatment of individuals with latent TB infection is crucial for TB elimination efforts.
• Pitfalls:
  • Delayed Diagnosis: Failure to consider TB, especially in atypical presentations or non-endemic areas, can lead to increased transmission and severe disease.
  • Non-Adherence: The most common reason for treatment failure, relapse, and development of drug resistance.
  • Inadequate Follow-up: Not monitoring for drug toxicity or treatment response can lead to complications or persistent disease.
  • Failure to Detect Drug Resistance: Starting an empiric first-line regimen without considering or testing for drug resistance can lead to treatment failure and selection of resistant strains.
  • Ignoring Co-morbidities: Failure to manage co-existing conditions (e.g., HIV, diabetes) or drug interactions can compromise TB treatment outcomes.

Recent Updates

• Guidelines:
  • WHO Consolidated Guidelines for TB Treatment (2022): Emphasize shorter, all-oral regimens for drug-resistant TB. For drug-susceptible TB, the 6-month regimen remains standard. Recommendations for shorter regimens for LTBI (e.g., 3HP).
  • CDC/ATS/IDSA Guidelines (2020): Provide updated recommendations for testing and treatment of LTBI, including 3HP and 4R as preferred regimens.
• Evidence:
  • Shorter LTBI Regimens: Strong evidence supporting 3 months of weekly isoniazid-rifapentine (3HP) or 4 months of daily rifampicin (4R) as preferred options over 6-9 months of daily isoniazid (6H/9H) due to higher completion rates and similar efficacy.
  • Molecular Diagnostics: Increasing adoption of rapid molecular tests (e.g., Xpert Ultra, Truenat) for initial diagnosis and resistance detection, particularly in extrapulmonary specimens.
  • All-Oral DR-TB Regimens: While outside the scope of "New TB Management," the shift towards all-oral, shorter (e.g., 6-9 months) regimens for drug-resistant TB is a significant recent advancement.
• Controversies:
  • Optimal Duration for Specific EPTB Forms: While 6 months is standard for most EPTB, optimal durations for less common or severe forms (e.g., TB pericarditis, intestinal TB) can still be debated in specific clinical contexts.
  • Role of Universal DST: The ideal extent of initial drug susceptibility testing (e.g., only rifampicin, or all first-line drugs, or even second-line) for all new TB cases is a topic of ongoing discussion and evolving recommendations, dependent on local epidemiology and resources.

Key References

• Guidelines:
  • World Health Organization (WHO). Global Tuberculosis Report 2023. Geneva: WHO; 2023. [Available at www.who.int/teams/global-tuberculosis-programme/tb-reports]
  • World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 1: prevention. Module 2: screening. Module 3: diagnosis. Module 4: treatment. Module 5: management of tuberculosis in children and adolescents. Module 6: treatment of latent tuberculosis infection. [Regularly updated versions available at www.who.int/teams/global-tuberculosis-programme/standards-and-tools/modules]
  • Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
  • Sterling TR, Njie G, White LF, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: An Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guideline. Clin Infect Dis. 2020;71(7):e1-e26.
  • Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Needs to Know. 2023. [Available at www.cdc.gov/tb/education/corecurr/index.htm]
• Studies:
  • Mase SR, Chorba T, Dorman SE, et al. Updated Guidance for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. Morbidity and Mortality Weekly Report. 2023;72(22):592-595.
  • Common aspects of major clinical trials related to 3HP regimen for LTBI (e.g., PREVENT TB, TBTC Study 26).
• Reviews:
  • Lange C, Saluzzo F, Dheda K, et al. Clinical management of tuberculosis. Lancet. 2022;399(10332):1323-1335.
  • Marais BJ, Schaaf HS. Tuberculosis in children. Cold Spring Harb Perspect Med. 2014;4(9):a017855.